Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

unknown1
Suspended1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (66.7%)
N/A1 (33.3%)

Trials by Status

unknown133%
suspended133%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_1

AD-SVF Therapy for Refractory Endometrial Infertility

NCT07230600
unknownphase_1

Cell Therapy for IBM by Muscle Injection of ADSVF

NCT05032131
suspendednot_applicable

The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine

NCT04064879

Clinical Trials (3)

Showing 3 of 3 trials
NCT07230600Phase 1

AD-SVF Therapy for Refractory Endometrial Infertility

Recruiting
NCT05032131Phase 1

Cell Therapy for IBM by Muscle Injection of ADSVF

Unknown
NCT04064879Not Applicable

The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine

Suspended

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3